SEC Form 4 · accession 0001104659-15-018783
CORGENIX MEDICAL CORP/CO · CONX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Stanley Tutag
Director
Period of report
Mar 10, 2015
Accepted (ET)
Mar 11, 2015 · 12:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001063665
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 10, 2015 | D | 961,000 | $0.27 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ''Right to buy'' common stock optionsF2 | $0.215 | Mar 10, 2015 | D | 40,000 | D | Aug 27, 2013 | Aug 27, 2020 | Common Stock | 40,000 | 0 | D |
| ''Right to buy'' common stock optionsF3 | $0.10 | Mar 10, 2015 | D | 40,000 | D | Aug 27, 2012 | Aug 27, 2019 | Common Stock | 40,000 | 0 | D |
| ''Right to buy'' common stock optionsF4 | $0.085 | Mar 10, 2015 | D | 40,000 | D | Aug 29, 2011 | Aug 29, 2018 | Common Stock | 40,000 | 0 | D |
| ''Right to buy'' common stock optionsF5 | $0.107 | Mar 10, 2015 | D | 40,000 | D | Sep 28, 2010 | Sep 28, 2017 | Common Stock | 40,000 | 0 | D |
| ''Right to buy'' common stock optionsF6 | $0.099 | Mar 10, 2015 | D | 40,000 | D | Oct 6, 2009 | Oct 6, 2016 | Common Stock | 40,000 | 0 | D |
Explanation of responses
- F1Disposed of in exchange for a cash payment of $0.27 per share pursuant to that certain Agreement and Plan of Merger, dated as of August 27, 2014, by and among Corgenix Medical Corp ("Corgenix"), Centennial Medical Holdings, Inc. ("Centennial") and Centennial Integrated, Inc., a wholly owned subsidiary of Centennial, pursuant to which Corgenix has been acquired by Centennial (the "Merger").
- F2This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of $2,200, representing (a) the number of shares underlying the option, multiplied by (b) the excess of $0.27 over the exercise price per share of the option (the "Option Merger Consideration").
- F3This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of $6,800, representing the Option Merger Consideration.
- F4This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of $7,400, representing the Option Merger Consideration.
- F5This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of $6,520, representing the Option Merger Consideration.
- F6This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of $6,840, representing the Option Merger Consideration.